Liver Biopsy Articles & Analysis: Older
6 news found
Patients in the first two Part B cohorts (200 and 400 mg quarterly) have completed at least 6 months on the study; remaining cohorts are exploring a lower dose or a later biopsy time point. In the first two Part B cohorts, ALN-HSD was associated with robust target knockdown and numerically lower liver enzymes and biopsy-derived nonalcoholic fatty ...
Key priorities in this development will be the completion of the clinical development programs that are already underway in liver and breast cancer and their regulatory approval, as well as thecompletion of the industrial scale-up in Europe and the US of the safe-biopsy device, which has already been clinically tested in lung and liver ...
Fin Posillipo (Petrone Group], Kairos Partners SGR, LIFTT, Neva Sgr (Intesa Sanpaoh Group), Profequycapital and Romedjoined the share capital Innogest Capital and Panakes Partners reinvest The financing will give BetaGlue Technologies the ability to further develop its advanced radiotherapy platform, BAT-90, and accelerate access to the Safe-Biopsy Device market, thus opening ...
Greater measurement depth of novel imaging test for liver disease highlighted in presentation Sonic Incytes Medical Corp. is pleased to announce that data from its sponsored clinical study of VelacurTM – the first handheld 3D liver health assessment solution – will be presented during the American Association for the Study of ...
Breakthrough imaging solution for liver health offers physicians an accurate, accessible and affordable way to manage emerging health crisis In recognition of Liver Awareness Month this October, Sonic Incytes Medical Corp. is pleased to showcase VelacurTM, the first handheld 3D liver health assessment solution, at the American College of ...
The patients received ParvOryx at three increasing dose levels, partly administered intravenously on four consecutive days, followed by an intrametastatic injection into a single liver metastasis after 6 to 13 days. After virotherapy, patients were treated with gemcitabine. ...